García-García HM, Vaina S, Tsuchida K, Serruys PW

Language: English
References: 104
Page: 297-319
PDF size: 394.51 Kb.

ABSTRACT

Stent implantation was developed to overcome the acute recoil and high restenosis rate of balloon angioplasty, but resulted in the development of chronic in-stent restenosis related to specific factors regarding patient, stent, lesion and procedural characteristics. Some factors are not modifiable, such as patient and lesion characteristics, whereas procedural characteristics may be improved by better implantation technique and stent design. Drugeluting stents are a novel approach in stent technology and design with local drug delivery to inhibit intimal thickening by interfering with different pathways involved in the development of inflammation, migration, proliferation and/or secretion of the extracellular matrix. Both the drug and the delivery vehicle must fulfill pharmacological, pharmacokinetic and mechanical requirements. Current successful drug eluting stents require a polymer coating for drug delivery. Clinical trials examining several pharmaceutical agents, particularly sirolimus and paclitaxel, have demonstrated marked reduction in restenosis following stenting. Sirolimus is a natural macrocyclic lactone and paclitaxel is a cytotoxic agent against many tumors. Both compounds block cell cycle progression and thus inhibit smooth muscle cell proliferation. The development of drug-eluting stents is one of the major revolutions in the field of Interventional Cardiology. Restenosis rate has been significantly reduced, in comparison to bare metal stents. The ideal drug to prevent restenosis must have an anti-proliferative and anti-migratory effect on smooth muscle cells but on the other hand must also enhance re-endothelialization, in order to prevent late thrombosis. Additionally, it should effectively inhibit the anti-inflammatory response after balloon induced arterial injury. Currently sirolimus, paclitaxel and more recently, ABT-578-eluting stents are commercially available, but ongoing research and clinical trials will result in new stents coming to market with novel designs loaded with a variety of compounds. As drug-eluting stent implantation becomes more liberal leading to an extensive use of this technology, the problem of restenosis in drug-eluting stents will become more common. However, for the time being, little is known regarding optimal treatment of in-stent restenosis following drug-eluting stent implantation. Future research is mandatory to further clarify, whether these patients should be treated with the same drug-eluting stent, with a different drug-eluting stent or with increased doses. Further improvements, including expansion of drug-loading capacity, coatings with programmable pharmacokinetic capacity and the discovery of new drugs may in the future further enhance the efficacy and safety of these stents. Although, drug-eluting stents have significantly reduced angiographic restenosis rate and have improved the clinical outcome, late thrombosis and restenosis remain an important subject of ongoing research. As drug-eluting stents are extensively used to treat all lesions, more efficacious agents and improved stent platforms are required. Synthetic or biological polymers can be used as matrixes for drug incorporation, but concerns have been raised regarding biocompatibility, sterility or potential induction of inflammation. Currently, alterations on stentbackbone design (biodegradable, bioabsorbable, nanoporous etc.) are being explored. Clearly, the anti-proliferative compounds sirolimus and paclitaxel have dominated up to date clinical practice, whereas their analogues are readily emerging. In the future, however, it is likely that drugs, currently under investigation, will address additional mechanisms associated with neointimal formation leading to restenosis, either as single agents or in combination with anti-proliferative compounds.

REFERENCES

1. DANGAS G, FUSTER V: Management of restenosis after coronary intervention. Am Heart J 1996; 132(2 Pt 1): 428-36.

2. KASTRATI A, MEHILLI J, DIRSCHINGER J, PACHE J, ULM K, SCHUHLEN H, ET AL: Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87(1): 34-9.

3. VAN BELLE E, BAUTERS C, ASAHARA T, ISNER JM: Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovasc Res 1998; 38(1): 54-68.

4. LIU MW, ROUBIN GS, KING SB, 3RD: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79(6): 1374-87.

5. FILIPPATOS G, PARISSIS JT, ADAMOPOULOS S, KARDARAS F: Chemokines in cardiovascular remodeling: clinical and therapeutic implications. Curr Mol Med 2003; 3(2): 139-47.

6. GALIS ZS, KHATRI JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3): 251-62.

7. WINSLOW RD, SHARMA SK, KIM MC: Restenosis and drug-eluting stents. Mt Sinai J Med 2005; 72(2): 81-9.

8. REGAR E, SIANOS G, SERRUYS PW: Stent development and local drug delivery. Br Med Bull 2001; 59: 227-48.

9. ROGERS CD: Optimal stent design for drug delivery. Rev Cardiovasc Med 2004; 5 Suppl 2: S9-S15.

10. SERRUYS PW, REGAR E, CARTER AJ: Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87(4):305-7.

11. GINGRAS AC, RAUGHT B, SONENBERG N: mTOR signaling to translation. Curr Top Microbiol Immunol 2004; 279: 169-97.

12. MORICE MC, SERRUYS PW, SOUSA JE, FAJADET J, BAN HAYASHI E, PERIN M, ET AL: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-80.

13. FAJADET J, MORICE MC, BODE C, BARRAGAN P, SERRUYS PW, WIJNS W, ET AL: Maintenance of longterm clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005; 111(8): 1040-4.

14. MOSES JW, LEON MB, POPMA JJ, FITZGERALD PJ, HOLMES DR, O’SHAUGHNESSY C, ET AL: Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349(14): 1315-23.

15. HOLMES DR, JR., LEON MB, MOSES JW, POPMA JJ, CUTLIP D, FITZGERALD PJ, ET AL: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109(5):634-40.

16. SCHAMPAERT E, COHEN EA, SCHLUTER M, REEVES F, TRABOULSI M, TITLE LM, ET AL: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43(6): 1110-5.

17. SCHOFER J, SCHLUTER M, GERSHLICK AH, WIJNS W, GARCIA E, SCHAMPAERT E, ET AL: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362(9390): 1093-9.

18. GIANNAKAKOU P, ROBEY R, FOJO T, MV B: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001; 20(29): 3806-13.

19. LANSKY AJ, COSTA RA, MINTZ GS, TSUCHIYA Y, MIDEI M, COX DA, ET AL: Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109(16): 1948-54.

20. GRUBE E, SILBER S, HAUPTMANN KE, MUELLER R, BUELLESFELD L, GERCKENS U, ET AL: TAXUS I: sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107(1): 38-42.

21. SERRUYS PW, DEGERTEKIN M, TANABE K, RUSSELL ME, GUAGLIUMI G, WEBB J, ET AL: Vascular responses at proximal and distal edges of paclitaxeleluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004; 109(5): 627-33.

22. STONE GW, ELLIS SG, COX DA, HERMILLER J, O’SHAUGHNESSY C, MANN JT, ET AL: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUSIV trial. Circulation 2004; 109(16): 1942-7.

23. HERMILLER JB, RAIZNER A, CANNON L, GURBEL PA, KUTCHER MA, WONG SC, ET AL: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005; 45(8): 1172-9.

24. STONE GW, ELLIS SG, CANNON L, GREENBERG JD, TIFT MANN JT, SPRIGGS D, ET AL: Outcomes of the Polymer-Based, Paclitaxel-Eluting Taxus Stent In Complex Lesions: Principal Clinical and Angiographic Results From the Taxus-V Pivotal Randomized Trial. 54th Annual Scientific Session 2005.

25. GRUBE E: Randomized Trial of Moderate-Rate Release Polymer-Based Paclitaxel-Eluting TAXUS stent for the Treatment of Longer Lesions. EUROPCR 2005, Paris, France 2005.

26. MORICE MC, SERRUYS PW, COLOMBO A, MEIER B, TAMBURINO C, GUAGLIUMI G, ET AL: Prospective Randomized Multi-Center Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus) (REALITY). Sunday, Mar 06, 2005. 2005; 54th ACC Annual Scientific Session, Orlando, USA.

27. WINDECKER S: SIRTAX: Randomized Comparison of a Sirolimus- vs a Paclitaxel-Eluting Stent for Coronary Revascularization. In: 54th ACC Annual Scientific Session; 2005; Orlando, USA; 2005.

28. DIBRA A, KASTRATI A, MEHILLI J, PACHE J, SCHUHLEN H, VON BECKERATH N, ET AL: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353(7): 663-70.

29. KASTRATI A, MEHILLI J, VON BECKERATH N, DIBRA A, PACHE J, SCHÜHLEN H, ET AL: ISAR-DESIRE: Drug-Eluting Stents for In-Stent Restenosis. In: European Society of Cardiology Congress 2004; 2004; Munich, Germany; 2004.

30. LEMOS PA, SERRUYS PW, VAN DOMBURG RT, SAIA F, ARAMPATZIS CA, HOYE A, ET AL: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the «real world»: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109(2): 190-5.

31. ONG AT, SERRUYS PW, AOKI J, HOYE A, VAN MIEGHEM CA, RODRIGUEZ-GRANILLO GA, ET AL: The unrestricted use of paclitaxel- versus sirolimuseluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45(7): 1135-41.

32. LEMOS PA, HOYE A, GOEDHART D, ARAMPATZIS CA, SAIA F, VAN DER GIESSEN WJ, ET AL: Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109(11): 1366-70.

33. CHIEFFO A, STANKOVIC G, BONIZZONI E, TSAGALOU E, IAKOVOU I, MONTORFANO M, ET AL: Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005; 111(6): 791-5.

34. VALGIMIGLI M, VAN MIEGHEM CA, ONG AT, AOKI J, GRANILLO GA, MCFADDEN EP, ET AL: Short- and longterm clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and TSEARCH). Circulation 2005; 111(11): 1383-9.

35. COLOMBO A, MOSES JW, MORICE MC, LUDWIG J, HOLMES DR JR, SPANOS V, ET AL: Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109(10): 1244-9.

36. SHARMA SK: Simultaneous kissing drug-eluting stent technique for percutaneous treatment of bifurcation lesions in large-size vessels. Catheter Cardiovasc Interv 2005; 65(1): 10-6.

37. NAKAMURA S, MUTHUSAMY TS, BAE JH, CAHYADI YH, UDAYACHALERM W, TRESUKOSOL D: Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol 2005; 95(2): 161-6.

38. GE L, IAKOVOU I, COSGRAVE J, CHIEFFO A, MONTORFANO M, MICHEV I, ET AL: Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005; 26(11): 1056-62.

39. WERNER GS, KRACK A, SCHWARZ G, PROCHNAU D, BETGE S, FIGULLA HR: Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 2004; 44(12): 2301-6.

40. HANEKAMP CE, KOOLEN JJ, DEN HEIJER P, SCHALIJ MJ, PIEK JJ, BAR FW, ET AL: Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study. Catheter Cardiovasc Interv 2003; 60(4): 452-7.

41. HOYE A, LEMOS PA, ARAMPATZIS CA, SAIA F, TANABE K, DEGERTEKIN M, ET AL: Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004; 16(5): 230-3.

42. GE L, IAKOVOU I, SANGIORGI GM, CHIEFFO A, MELZI G, COSGRAVE J, ET AL: Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005; 45(7): 989-94.

43. TSUCHIDA K, ONG AT, AOKI J, VAN MIEGHEM CAG, RODRIGUEZ-GRANILLO GA, VALGIMIGLI M, ET AL: Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005; (in press).

44. DEGERTEKIN M, REGAR E, TANABE K, SMITS PC, VAN DER GIESSEN WJ, CARLIER SG, ET AL: Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003; 41(2): 184-9.

45. SOUSA JE, COSTA MA, ABIZAID A, SOUSA AG, FERES F, MATTOS LA, ET AL: Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107(1): 24-7.

46. SAIA F, LEMOS PA, ARAMPATZIS CA, HOYE A, DEGERTEKIN M, TANABE K, ET AL: Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004; 90(10): 1183-8.

47. NEUMANN FJ, DESMET W, GRUBE E, BRACHMANN J, PRESBITERO P, RUBARTELLI P, ET AL: Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005; 111(16): 2107-11.

48. TANABE K, SERRUYS PW, GRUBE E, SMITS PC, SELBACH G, VAN DER GIESSEN WJ, ET AL: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107(4): 559-64.

49. KOMATSU R, UEDA M, NARUKO T, KOJIMA A, BECKER AE: Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analysis. Circulation 1998; 98(3): 224-33.

50. ONG AT, HOYE A, AOKI J, VAN MIEGHEM CA, RODRIGUEZ-GRANILLO GA, SONNENSCHEIN K, ET AL: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45(6): 947-53.

51. BAVRY AA, KUMBHANI DJ, HELTON TJ, BHATT DL: What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45(6): 941-6.

52. MORENO R, FERNANDEZ C, HERNANDEZ R, ALFONSO F, ANGIOLILLO DJ, SABATE M, ET AL: Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45(6): 954-9.

53. IAKOVOU I, SCHMIDT T, BONIZZONI E, GE L, SANGIORGI GM, STANKOVIC G, ET AL: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293(17): 2126-30.

54. MCFADDEN EP, STABILE E, REGAR E, CHENEAU E, ONG AT, KINNAIRD T, ET AL: Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364(9444): 1519-21.

55. ONG AT, MCFADDEN EP, REGAR E, DE JAEGERE PP, VAN DOMBURG RT, SERRUYS PW: Late angiographic stent thrombosis (LAST) events with drugeluting stents. J Am Coll Cardiol 2005; 45(12): 2088-92.

56. SERRUYS PW, ONG AT, COLOMBO A, DAWKINS K, DE BRUYNE B, FAJADET J, ET AL: Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents for the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. EuroIntervention 2005; 2: 146-157.

57. ONG AT, SERRUYS PW, MOHR FW, MORICE MC, KAPPETEIN AP, HOLMES DR, ET AL: The SYNergy between Percutaneous Coronary Intervention with TAXusT and Cardiac Surgery (SYNTAX) Study: Design, Rationale and Run-In Phase. Am Heart J 2005; (in press).

58. HEUBLEIN B, ROHDE R, KAESE V, NIEMEYER M, HARTUNG W, HAVERICH A: Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003; 89(6): 651-6.

59. DI MARIO C, GRIFFITHS H, GOKTEKIN O, PEETERS N, VERBIST J, BOSIERS M, ET AL: Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 2004; 17(6): 391-5.

60. ERBEL R: Coronary results of the first absorbable metal stent: The Progress-I trial. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, USA 2006.

61. AGRAWAL CM, HAAS KF, LEOPOLD DA, CLARK HG: Evaluation of poly (L-lactic acid) as a material for intravascular polymeric stents. Biomaterials 1992; 13(3): 176-82.

62. VOGT F, STEIN A, RETTEMEIER G, KROTT N, HOFFMANN R, VOM DAHL J, ET AL: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004; 25(15): 1330-40.

63. TAMAI H, IGAKI K, KYO E, KOSUGA K, KAWASHIMA A, MATSUI S, ET AL: Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102(4): 399-404.

64. SERRUYS PW: Drug-Eluting Stents: Results from Clinical Trials. The PISCES Trials. 55th Annual Scientific Session of ACC. Atlanta, USA 2006.

65. WIENEKE H, DIRSCH O, SAWITOWSKI T, GU YL, BRAUER H, DAHMEN U, ET AL: Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003; 60(3): 399-407.

66. KOLLUM M, FARB A, SCHREIBER R, TERFERA K, ARAB A, GEIST A, ET AL: Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005; 64(1): 85-90.

67. WESSELY R, HAUSLEITER J, MICHAELIS C, JASCHKE B, VOGESER M, MILZ S, ET AL: Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25(4): 748-53.

68. HAUSLEITER J, KASTRATI A, WESSELY R, DIBRA A, MEHILLI J, SCHRATZENSTALLER T, ET AL: Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005; 26(15): 1475-81.

69. SERRUYS PW, SIANOS G, ABIZAID A, AOKI J, DEN HEIJER P, BONNIER H, ET AL: The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005; 46(2): 253-60.

70. KAUL U: Erodablepolymer-reservoir Paclitaxeldrug eluting stents II: Cobalt chromium platforms in complex lesions. In: TCT; 2004; Washington, USA; 2004.

71. SERRUYS PW: The new CoStar TM stent: 12 month results with the new DES technology. In: EuroPCR 2005; 2005; Paris, France; 2005.

72. DAWKINS K: The Eurostar trial. In: EuroPCR 2005; 2005; Paris, France; 2005.

73. GAMBHIR DS: The Infinnium polymere-based paclitaxel drug-eluting stent: Results from real world clinical trials SIMPLE 1 and SIMPLE 2. In: TCT2004; 2004; Washington, USA; 2004.

74. LELE S: Heparin Sirolimus Stent. EuroPCR2006. Paris, France 2006.

75. WINDECKER S, MAYER I, DE PASQUALE G, MAIER W, DIRSCH O, DE GROOT P, ET AL: Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001; 104(8): 928-33.

76. WINDECKER S, SIMON R, LINS M, KLAUSS V, EBERLI FR, ROFFI M, ET AL: Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005; 111(20): 2617-22.

77. MEREDITH IT, ORMISTON J, WHITBOURN R, KAY P, MULLER D, POPMA JJ, ET AL: ENDEAVOR I «firstin-human» safety and efficacy study. 12-month clinical, angiographic, and intravascular ultrasound results. Circulation 2004; 110: III-563-III-564.

78. FAJADET J, WIJNS W, LAARMAN GJ, KUCK KH, ORMISTON J, MÜNZEL T, POPMA JJ, FITZGERALD PJ, BONAN R, KUNTZ RE. For the ENDEAVOR II Investigators. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions. Circulation 2006;114:798-806.

79. KANDZARI DE: Overview of ABT-578/PC/Cobalt Technology and Clinical Trial Program. 55th Annual Scientific Session of ACC. Atlanta, USA 2006.

80. KANDZARI DE, LEON MB: ENDEAVOR III. A Randomized Trial to Confirm the Safety and Efficacy of the Medtronic Zotarolimus Eluting Stent in De Novo Native Coronary Artery Lesions. 17th Transcatheter Cardiovascular Therapeutics Scientific Symposium. Washington, D.C., USA 2005.

81. ABIZAID A, LANSKY A, FITZGERALD P, ET AL: Percutaneous coronary revascularization using a trilayer phosphorylocholine-coated zotarolimus-eluting stent: The ZoMaxx IVUS trial. 55th Annual Scientific Session of ACC. Atlanta, USA 2006.

82. COSTA RA, LANSKY AJ, MINTZ GS, MEHRAN R, TSUCHIYA Y, NEGOITA M, ET AL: Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95(1): 113-6.

83. GRUBE E, SONODA S, IKENO F, HONDA Y, KAR S, CHAN C, ET AL: Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004; 109(18): 2168-71.

84. GRUBE E: FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. In: TCT; 2003; Washington, USA; 2003.

85. SERRUYS PW, ONG ATL, PIEK JJ, NEUMANN FJ, VAN DER GIESSEN WJ, WIEMER M, ET AL: A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1(1): 58-69.

86. GRUBE E, HAUPTMANN KE, BUELLESFELD L, LIM V, ABIZAID A: Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9T eluting stent with a biodegradable polymer coating. EuroIntervention 2005; 1: 53-7.

87. STEPKOWSKI SM: Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000; 2000: 1-23.

88. MORICE MC: JUPITER II Trial. Six-month interim clinical data. In: EuroPCR 2005; 2005; Paris, France; 2005.

89. AOKI J, SERRUYS PW, VAN BEUSEKOM H, ONG AT, MCFADDEN EP, SIANOS G, ET AL: Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005; 45(10): 1574-9.

90. DUCKERS E: Endothelial progenitor cell capture (EPC): update and perspectives. EuroPCR. Paris, France 2005.

91. LIU X, HUANG Y, HANET C, VANDORMAEL M, LEGRAND V, DENS J, ET AL: Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003; 60(2): 172-8; discussion 179.

92. DE SCHEERDER I: The Abbott Vascular Devices Dexamethasone Eluting Stent: From STRIDE to the “Real-world” SAFE Registry. Transcatheter Therapeutics Scientific Sessions. Washington, USA 2003.

93. LEFER AM, SCALIA R, LEFER DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49(2): 281-7.

94. TANABE K, ISHIYAMA H, VAN DER GIESSEN W, SERRUYS PW: Terumo statin releasing stent (preclinical results). In: SERRUYS PW, GERSHLICK A, EDITORS. Drug-Eluting Stents. London: Taylor and Francis Group; 2005: 313-321.

95. KIPSHIDZE NN, IVERSEN P, KIM HS, YIAZDI H, DANGAS G, SEABORN R, ET AL: Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv 2004; 61(4): 518-27.

96. KIPSHIDZE N, OVERLIE P, DUNLAP T, TITUS B, LEE D, LAUER M: First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: Six-month clinical and angiographic follow-up from AVAIL study. In: American Heart Association, Scientific Sessions 2004; 2004; New Orleans, USA; 2004.

97. REGAR E, SERRUYS PW, BODE C, HOLUBARSCH C, GUERMONPREZ JL, WIJNS W, ET AL: Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106(15): 1949-56.

98. COLOMBO A, DRZEWIECKI J, BANNING A, GRUBE E, HAUPTMANN K, SILBER S, ET AL: Randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108(7): 788-94.

99. STONE GW, ELLIS SG, COX DA, HERMILLER J, O’SHAUGHNESSY C, MANN JT, ET AL: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350(3): 221-31.

100. MORICE MC, SERRUYS PW, COSTANTINI C, WUELFERT E, WIJNS W, FAJADET J, ET AL: Two-Year FollowUp of the RAVEL Study: A Randomized Study With the Sirolimus-Eluting Bx VELOCITYT Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions. J Am Coll Cardiol 2003; 41(6(Suppl A)): 32A [abstract].

101. MORICE MC, SERRUYS PW, SOUSA JE, FAJADET J, BAN HAYASHI E, PERIN M, ET AL: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-80.

102. MEREDITH I: Endeavor DES Program. Endeavor I-IV summary update. In: TCT2004; 2004; Washington, USA; 2004.

103. CHEVALIER B: ZoMaxx: global and clinical programme development. In: Euro PCR 2005; 2005; Paris, France; 2005.

104. GRUBE E: FUTURE Clinical Trials. Champion TM Everolimus Eluting Coronary Stent System. In: TCT2004; 2004; Washington, USA; 2004.